← Back
$LGND All transactions

LIGAND PHARMACEUTICALS INC

▲ BUY
7 / 10

Conviction

$ Value

$176K

Shares

1,680

Price

$105

Filed

May 13

Why this score? (7/10)
  • Open market buy (+3)
  • C-suite insider (+2)
  • Director (+1)
  • Not a 10b5-1 plan (+1)

Insider

Name

Davis Todd C

Title

Chief Executive Officer

CIK

0001392029

Roles

Director Officer

Transaction Details

Transaction Date

2025-05-09

Code

P

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

153,404

Footnotes

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $104.1300 to $105.1000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $105.1300 to $106.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Filing Info

Accession No.

0002001011-25-000029

Form Type

4

Issuer CIK

0000886163

Davis Todd C's History

Date Ticker Type Value
2026-03-02 LGND A $0
2026-03-02 LGND A $0
2025-12-04 LGND G $0
2025-07-02 PTHS A $0
2025-07-02 PTHS A
2025-07-02 PTHS A
2025-07-01 PTHS C $15.0M
2025-07-01 PTHS C $0
2025-07-01 PTHS J
2025-06-30 LGND J $21K

Other Insiders at LGND (90d)

Insider Bought Sold Last
LAMATTINA JOHN L $434K 2026-03-06
KOZARICH JOHN W $94K 2026-04-01
Davis Todd C
Chief Executive Officer
2026-03-02
Sabba Stephen L $208K 2026-03-23
Espinoza Octavio
Chief Financial Officer
2026-03-02
Reardon Andrew
CLO & Secretary
$1.0M 2026-04-01